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Abstract 21 
IQGAPs are eukaryotic proteins which integrate signals from various sources and pass these 22 
on the cytoskeleton.  Understanding how they do this requires information on the interfaces 23 
between the proteins.  Here, it is shown that the calponin homology domain of human 24 
IQGAP1 (CHD1) can be crosslinked with α-actin.  The stoichiometry of the interaction was 25 
1:1.  A molecular model was built of the complex and associated bioinformatics analyses 26 
predicted that the interaction is likely to involve an electrostatic interaction between Lys-240 27 
of α-actin and Glu-30 of CHD1.  These residues are predicted to be accessible and are not 28 
involved in many intra-protein interactions; they are thus available for interaction with 29 
binding partners.  They are both located in regions of the proteins which are predicted to be 30 
flexible and disordered; interactions between signalling molecules often involve flexible, 31 
disordered regions.  The predicted binding region in CHD1 is well conserved in many 32 
eukaryotic IQGAP-like proteins.  In some cases (e.g Dictyostelium discoideum and 33 
Saccharomyces cerevisiae) protein sequence conservation is weak, but molecular modelling 34 
reveals that a region of charged, polar residues in a flexible N-terminus is structurally well 35 
conserved.  Therefore we conclude that the calponin homology domains of IQGAP1-like 36 
proteins interact initially through the electrostatic interaction identified here and that there 37 
may be subsequent conformational changes to form the final complex. 38 
 39 
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The human cytoskeletal scaffolding protein, IQGAP1 is known to 
interact with actin.  Using a combined crosslinking and computational 
approach, we predicted the site of interaction.  This work was 
extended to other members of the IQGAP family. 
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Introduction 42 
The IQGAPs are a family of cytoskeletal scaffolding proteins in fungi and animals [1-10].  43 
The name IQGAP is derived from two of the domains present in this group of proteins: the 44 
IQ, and the Ras GTPase-activating (GAP) related domains. They link a diverse range of 45 
signalling pathways, including calcium-calmodulin, small GTPases, kinases and growth 46 
factor receptors to the actin cytoskeleton [11-24].  In addition, they also help control the 47 
microtubule system indirectly through CLIP-170 and APC [25, 26].  Not surprisingly, since 48 
they sit at the interface of many cellular processes, they have been implicated in diseases 49 
including cancer, heart disease and infection by bacteria and viruses [27-33].  In the last 50 
decade, considerable advances have been made in the understanding of the IQGAP family’s 51 
cellular roles.  This is especially true of the best characterised member of the family, human 52 
IQGAP1.  However, many molecular-level details remain to be discovered.  Although high 53 
resolution structures are available for some domains, there is no structure of a complete 54 
IQGAP; therefore there is little information about how the various domains in the protein 55 
communicate [34-37].  There is also only limited data available on how the protein interacts 56 
with its many binding partners.  Such information would illuminate cellular level studies and 57 
may be of value in the event that it is shown to be desirable to disrupt these interactions for 58 
the development of novel anti-cancer or anti-infective drugs. 59 
 60 
It is known that interaction with actin occurs through the calponin homology domain (CHD), 61 
located at the N-terminus of the protein [13, 38, 39].  The functional consequence of this 62 
interaction is the bundling of actin filaments [40-42].  The CHD also provides an interaction 63 
site for calmodulin, although this protein interacts primarily through IQ-motifs located 64 
towards the middle of the primary sequence [13, 43, 44].  Here a crosslinking protocol was 65 
used to confirm the actin/CHD interaction and determine its stoichiometry.  Molecular 66 
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modelling of the complex between the two molecules was undertaken to predict the site of 67 
interaction. 68 
 69 
Materials and Methods 70 
Proteins 71 
A protein containing residues 2-215 from human IQGAP1 (which encompass the CHD and is 72 
referred to as CHD1 hereafter) was expressed in, and purified from, Escherichia coli as 73 
described previously [44].  Rabbit skeletal muscle actin was purchased from Cytoskeleton 74 
Inc. (Denver, CO, USA) as freeze dried powder.  The powder was reconstituted in G-actin 75 
buffer (5 mM Tris-HCl, pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, 0.5 mM DTT) to a final 76 
concentration of 1 mg ml-1, placed on ice for 60 min and then centrifuged at 13,000 g at 4 ºC 77 
for 15 min.  The supernatant was removed and assumed to be G-actin.  Protein concentrations 78 
were estimated by the method of Bradford [45], using BSA as a standard. 79 
 80 
Crosslinking 81 
Actin (23 μM) and CHD1 (27 μM) were mixed and incubated at 37 ºC for 60 min.  After this 82 
time, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was added to a final 83 
concentration of 70 mM and the reaction allowed to proceed for 60 min.  The reaction was 84 
stopped by the addition of SDS-PAGE loading buffer (120 mM TrisHCl pH 6.8, 4% (w/v) 85 
SDS, 20% (v/v) glycerol, 5% (w/v) bromophenol blue, 1% (w/v) DTT) and heating at 95 ºC 86 
for 5 min.  Results were analysed by SDS-PAGE. 87 
 88 
Mass spectrometry 89 
The gel band was excised and cut into 1 mm cubes.  These were then subjected to in-gel 90 
digestion, using a ProGest Investigator in-gel digestion robot, using standard protocols.  91 
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Briefly the gel cubes were destained by washing with acetonitrile and subjected to reduction 92 
and alkylation before digestion with trypsin at 37°C. The peptides were extracted with 10% 93 
formic acid and concentrated down to 20 µL (SpeedVac, ThemoSavant). They were then 94 
separated using an UltiMate nanoLC (LC Packings, Amsterdam) equipped with a PepMap 95 
C18 trap & column, using a 60 min gradient of increasing acetonitrile concentration, 96 
containing 0.1 % formic acid (5-35% acetonitrile in 35 min respectively, 35-50% in a further 97 
20 min, followed by 95% acetonitrile to clean the column).  The eluant was sprayed into a Q-98 
Star XL tandem mass spectrometer (Applied Biosystems, Foster City, CA) and analysed in 99 
Information Dependent Acquisition (IDA) mode, performing 1 sec of MS followed by 3 sec 100 
MSMS analyses of the 2 most intense peaks seen by MS. These masses are then excluded from 101 
analysis for the next 60 sec. MS/MS data for doubly and triply charged precursor ions was 102 
converted to centroid data, without smoothing, using the Analyst QS1.1 mascot.dll data import 103 
filter with default settings.  The MS/MS data file generated was analysed using the Mascot 2.1 104 
search engine (Matrix Science, London, UK) against the UniRef 100 database, Jan 2008 105 
(5247086 sequences) with no species restriction.  The data was searched with tolerances of 106 
0.2 Da for the precursor and fragment ions, trypsin as the cleavage enzyme, one missed 107 
cleavage, carbamidomethyl modification of cysteines as a fixed modification and methionine 108 
oxidation selected as a variable modification. 109 
 110 
Molecular modelling of the actin and IQGAP1 CHD interface 111 
Models of human IQGAP1 residues 2 - 215 and rabbit skeletal muscle α-actin (which is 112 
100% identical to the human α-actin sequence; UniProt accession numbers:  human P46940, 113 
rabbit P68135) were constructed using the Phyre2 server in intensive mode [46] and 114 
displayed using PyMol (www.pymol.org). These were then minimised using the YASARA 115 
force field [47].  Patchdock was utilised in the docking of ADP with actin and Firedock for 116 
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refining of these results [48, 49]. The first, most energetically favourable result was taken and 117 
minimised using YASARA. Protein flexibility was predicted using FRODAN to generate 500 118 
conformers in the momentum mode [50]. The HADDOCK flexible docking server was used 119 
to model potential interactions between actin and CHD1 [51]. The postulated binding regions 120 
were used as targets and HADDOCK was set to define its own passive interacting residues. 121 
Only the most energetically favourable structure was used. Models were subjected to the 122 
structure validation tools of the WHATIF server to check for potential collisions and to 123 
validate bond lengths, planarity and dihedral angles of residues [52]. The xWalk algorithm 124 
was used to calculate Euclidean distances between the potential cross linked residues in the 125 
HADDOCK structure, whilst the ESBRI and PIC solvent accessibility tools allowed 126 
calculation of potential salt bridges and solvent accessibility of the residues respectively [53-127 
55]. Residue accessibility was calculated using GETAREA [56].  128 
 129 
Multiple sequence alignment, structural alignments, residue conservation and in silico 130 
prediction of probable interacting residues 131 
Multiple sequence alignment of CHDs was carried out using Clustal Omega [57, 58]. 132 
Sequences were obtained from NCBI using the psiBLAST tool to obtain distant members of 133 
the eukaryotic lineage [59]. Sequences that were true IQGAP1 homologues and IQGAP1-like 134 
proteins were used as well as the other human and mouse isoforms. The alignment was used 135 
along with the Scorecons server to calculate residue conservation at each position based upon 136 
the Valdar01 score [60]. The EMBOSScons tool (http://www.ebi.ac.uk/emboss) allowed for a 137 
consensus sequence of the region to be deduced. Models of the aligned sequences were built 138 
in Phyre2 and minimised for use in structural alignments. These were carried out in PyMol 139 
using the align function. The WHATIF server was used to calculate residue accessibility in 140 
both actin and CHD1 [52]. The programs DisEMBL and DISOclust were employed to 141 
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calculate intrinsically disordered domains in the models [61, 62]. The ProFace server was 142 
used to analyse the HADDOCK model and to provide the most probable interface residues 143 
[63]. NNcon is a program that was used to analyse and provide a readout of intraprotein 144 
interactions. Therefore, it was used to identify residues which were not involved in 145 
intraprotein contacts and which will, therefore, be more available for protein-protein 146 
interactions [64].  147 
 148 
Prediction of the biochemical effects of missense mutations on the IQGAP1 CHD  149 
The WHATIF server was used to mutate the potential cross linked residues in the CHD1 to 150 
alanines. The resulting model was subject to analysis using the MuPro, SNPeffect and Site 151 
directed mutator programs in order to predict potential effects on the protein’s functionality 152 
[52, 65-67]. The SNPeffect server uses four different programs: TANGO looks at how a 153 
given mutation affects the propensity of a protein to aggregate, WALTZ focuses on the 154 
effects the mutation may have on the tendency of a protein to form amyloids, LIMBO looks 155 
at changes in a proteins ability to bind chaperones and FOLDX analyses the overall effects of 156 
the mutation on the proteins stability. The mutated CHD model was also docked to actin 157 
using HADDOCK (as described above for the wild type protein) in order to predict changes 158 
in predicted energies and root mean square deviations (rmsd).  159 
 160 
Results 161 
Actin and the CHD from IQGAP1can be crosslinked 162 
When actin and CHD1 were mixed in the presence of the crosslinker EDC, an additional 163 
band was observed at ~70 kDa (figure 1).  This band did not appear when the proteins were 164 
mixed in the absence of crosslinker or when each protein alone was exposed to EDC.  165 
Therefore, it is likely to correspond to the covalently linked actin-CHD1 complex.  The 166 
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estimated molecular mass of the complex is consistent with it containing one molecule of 167 
actin (42 kDa) and one of CHD1 (26 kDa including the hexahistidine tag). 168 
 169 
Bands were excised from these gels and subjected to in-gel digestion with trypsin and the 170 
resultant peptides analysed by mass spectrometry.  Bands corresponding to CHD1 plus 171 
crosslinker and actin plus crosslinker resulted in 22 and 26 peptides with Mascot Ion Scores 172 
above the Identity threshold (95% confidence) matching to each sequence respectively. In the 173 
band corresponding to the postulated crosslinked complex, peptides from both actin (16 174 
peptides) and CHD1 (7 peptides) could be identified.  This confirmed that the additional band 175 
did, indeed, correspond to an actin-CHD1 complex.  Interestingly, only peptides from α-actin 176 
were isolated; therefore bioinformatics and modelling studies concentrated on this isoform. 177 
 178 
CHD1 and actin models were docked to predicted interaction sites 179 
Phyre2 modelled both proteins with greater than 90% accuracy and these were virtually 180 
indistinguishable from the experimental structures following minimisations and alignment. 181 
Both models were validated successfully by the WHATIF server. 182 
 183 
The HADDOCK server docked the structure and the first, most favourable result, with a Z-184 
Score of -2.2 was taken and minimised using YASARA. xWalk was then utilised to find the 185 
closest point of contact and this was shown to be between Lys-240 of actin and Glu-30 of 186 
CHD1 at a Euclidean distance of 5.2 Å. The HADDOCK predicted complex is shown in 187 
Figure 2. The top complex highlights residue Lys 240 of actin and residues Glu 29, 30, 33, 188 
and Asp 32 of CHD whilst the bottom complex presents the docked structure with a semi-189 
transparent overlay of the surface of the two proteins.. xWalk showed that the solvent 190 
accessible surface distance is 4.5 Å; a similar result was calculated by ESBRI (4.45 Å). The 191 
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PIC solvent accessibility tool validated these residues as being capable of ionic interaction.  192 
While this alone does not prove that these two residues are part of the interaction site it is 193 
consistent with the favourable HADDOCK energies associated with the docking process 194 
(Table 1).  Thus the model shown in figure 2 is a feasible representation of part of the 195 
interface between actin and CHD1. 196 
 197 
Any interaction site must be accessible in order to take part in a given interaction either 198 
directly or following a conformational change exposing the site. Given this, the relative 199 
accessibility of residues can be a good indicator of whether, or not, they can take part in 200 
initial interactions. The accessibility of the actin and CHD1 residues of interest are given in 201 
Table 2 as side, back and total overall residue accessibility. Of particular interest are charged 202 
residues in the potential binding sites which are potentially crosslinkable by EDC.  Residues 203 
Glu-239 and Lys-240 of actin showed good overall accessibility (27.7 and 37.2 Å2 total 204 
accessibility respectively) as did the residues Glu-29, Glu-30, Glu-33 and Asp-32 (41.7, 38.0, 205 
13.5 and 44.8 Å2 total accessibility respectively) of CHD1. It therefore seems likely that all 206 
these residues are available and are potentially involved in the initial interaction. The Proface 207 
analyser provides a readout of residues involved in the interface of the docked structure. The 208 
results from this prediction are shown in Supplementary Figure S1 and include residues 28, 209 
30, 31, 32, 33, 34 from CHD1 and residues 237, 239 and 240 from the actin. The NNcon 210 
program showed that up to residue 180 in actin there was generally potential for >10 211 
intraprotein contacts between each amino acid and others within the protein. In some cases 212 
there was >40 predicted interactions. After residue 180, the number of potential interactions 213 
per residue fell with some not taking part in any. For the putative actin site, residues 237, 214 
238, 239 and 240 were shown to take part in 0, 4, 4 and 5 intraprotein interactions 215 
respectively.  For CHD1, a block of residues from 21-26 and 28-43 inclusive are predicted to 216 
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not be involved in any intraprotein interactions. These are the only large blocks of this nature 217 
in the whole of the CHD1. Thus, the predicted binding regions in both proteins are free to 218 
take part in protein – protein interactions. 219 
 220 
The putative binding sites are predicted to be highly flexible 221 
The interaction sites between proteins often involve highly mobile, flexible regions.  This is 222 
often the case in signalling proteins where high specificity but short-lived interactions are 223 
required [68-70].  When interpreting flexibility predictions it is important to look at the 224 
flexibility of localised regions as opposed to limiting the analysis to individual residues. 225 
FIRST/FRODAN predicted that CHD1 has three highly flexible regions, which are the 226 
termini and a zone localised around residues 92-110 (Figure 3a). However, the N-terminus 227 
shows extraordinary flexibility and this extends almost as far as residue 40 and peaks at an 228 
rmsd of 9.2 Å for Arg-24 (Figure 3b). The results for actin are equally intriguing. It is clear 229 
that it is a highly dynamic molecule but two regions stand out, which are those around 230 
residue 50 and the larger region spanning residues 224-250.  The rmsd peaked at 7.8 Å at 231 
Ala-233. The regions correspond to the two lobes in actin with the one around residue 50 232 
being the DNase I binding loop [71]. The predicted interaction regions from both proteins 233 
therefore lie within the predicted areas of greatest flexibility. It is possible that, given the high 234 
flexibility of the two regions, all residues interact to varying extents by transient hydrogen 235 
bonds and other non-covalent interactions. This may therefore be the initial interaction that 236 
takes place between CHD1 and actin before a conformational change exposes other actin 237 
binding sites. 238 
 239 
The CHD1 and Actin sites show high levels of intrinsic disorder 240 
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Intrinsic disorder was first calculated using DisEMBL which carries out these predictions 241 
based upon three definitions of disorder [61]. Both actin and CHD1 disorders were calculated 242 
for the loops/coils, hot loops and remark-465 definitions (Supplementary Figure S2). For 243 
CHD1 there is extensive disorder for the loops/coils definition, significantly less for the hot 244 
loops and none for the remark-465 definition (Supplementary Figure S2a). The remark-465 245 
definition is less relevant in this case as it is generally only compatible with actual X-ray data 246 
[61]. The hot loops definition is the most significant as this is a refinement of the first 247 
loops/coils data. For CHD1, the fragment LTAEEM is implicated as being disordered. For 248 
actin the results are much more profound. Only 13% of actin is disordered by the hot loops 249 
definition and this includes the region TAASSSSLEK. 250 
 251 
The DISOclust results add weight to the above predictions (Figure 3c,d) because they also 252 
implicated the postulated regions. DISOclust scores are only stated to be of significance if 253 
they exceed the 50% threshold mark [62]. The CHD1 plot looks not unlike the FRODAN 254 
results and it is common for disordered regions to also be highly flexible due to the lack of 255 
three-dimensional structure. The postulated CHD1 binding site clearly lies within the 256 
disordered region. Apart from the ends, only one other region in actin exceeds the DISOclust 257 
threshold, residues 227-244 (Figure 3c). 258 
 259 
Taken together, these predictions show that both the actin and CHD1 sites form part of 260 
intrinsically disordered domains that are surface exposed.  This may also implicate these 261 
regions in binding of other partners. 262 
 263 
In silico mutagenesis of the CHD1 site is stabilising and preserves overall structure, but is 264 
predicted to reduce interaction with actin 265 
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The residues Glu 29, 30, 33 and Asp 32 of CHD1 were mutated in silico to alanines using the 266 
WHATIF mutate a residue tool [52]. MuPro [65] was used to analyse the effect of each of the 267 
above mutations individually by predicting the change in the conformational stability of the 268 
protein (ΔΔG value). MuPro predicted that each mutation would individually cause an 269 
increase in the stability of the protein. The original and WHATIF model were then submitted 270 
to the SDM server [67] and this too predicted that the protein would increase in stability but 271 
also that it would most likely to be non-functional as a result (data not shown). 272 
 273 
The SNPeffect server showed that the mutations have no effect on aggregation tendency, 274 
amyloid propensity or the ability of the protein to bind chaperones. The FOLDX component, 275 
however, predicted that the protein would increase slightly in stability. The fact that these 276 
mutations were predicted to cause an increase in stability was surprising since it is common 277 
for amino acid changes to destabilise proteins. However, in this case, it is possible that the 278 
mutations cause an increase in stability via an elimination of charge repulsion between the 279 
glutamates and aspartate.  This, combined with the shorter alanine side chain, may enable the 280 
protein to adopt a slightly more compact and stable structure that does not cause malign 281 
effects such as aggregation. The loss of these potential interacting residues, the stability 282 
changes and likely decrease in flexibility were postulated to diminish interaction with actin. 283 
 284 
The mutated structure was taken and docked with wild type actin using HADDOCK using the 285 
same docking parameters as wild type. The results were intriguing (Table 1) as there was a 286 
substantial drop in electrostatic and Van der Waals energies, with the mutant-actin complex 287 
having less than half the electrostatic energy of the complex with wild type. It is clear that 288 
docking of the mutant is an unfavourable process compared to the wild type.  289 
 290 
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Implications for calponin homology domains from IQGAP-like proteins from other species 291 
Sequence alignments, between analogous proteins from different species, often identify the 292 
functional, structural and/or evolutionary relationships between them [72]. Actin is one of the 293 
most conserved eukaryotic proteins and as such it would be difficult to deduce potential 294 
binding sites from structural and sequence information alone. CHD1 is not as strongly 295 
conserved and some inferences can be drawn from its alignment. Sequences were compared 296 
for the human IQGAP isoforms and lower eukaryotes such as Trachipleistophora hominis 297 
and Caenorhabditis elegans (Supplementary Figure S3). It is be immediately obvious that 298 
there is reasonable conservation of the region, especially the aspartate and adjacent 299 
glutamate, and also a block of arginine residues following the postulated interaction region. 300 
These arginines may also be involved in the interaction. When the EMBOSScons sequence 301 
tool was used, it generated VDDERLSAEEMDERRR as the consensus sequence. The 302 
Scorecons server shows 0.413, 0.627, 0.685, 0.612, 0.684, 0.921, 1.000, 0.912, 0.611, 1.000 303 
and 0.640 as conservation values for the residues LTAEEMDERRR. In many cases, when a 304 
residue is not conserved in a sequence it is replaced by an amino acid that could carry out the 305 
same function e.g. polar threonine for serine, aspartate instead of glutamate and glutamine or 306 
lysine instead of arginine. 307 
 308 
However, when the CHD from the budding yeast (Saccharomyces cerevisiae) IQGAP-like 309 
protein, Iqg1p, is aligned the following sequence lines up with the postulated actin binding 310 
region:  KYTVDLSNYSKIELRYYEF. This does contain largely polar and charged residues 311 
and could be involved in the interaction, but the lack of precise sequence alignment means 312 
that there must be differences between this protein and those from higher eukaryotes. 313 
However, given that sequence defines structure, structure defines function and that different 314 
sequences may produce similar overall structures, the structural alignment of proteins is often 315 
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a much better indicator of deducing functionally equivalent sites. Therefore, Phyre2 was used 316 
to construct models of CHDs from a variety of species and, following minimisation, these 317 
were aligned to the human structure using PyMol. The predicted structures of human CHD1 318 
aligned with the equivalent regions from IQGAP-like proteins from C. elegans, Hydra 319 
vulgaris, and S. cerevisiae are shown in Figure 4a,b,c. Although the S. cerevisiae sequence 320 
aligns only poorly with the human one, it is clear that the structures do align and, 321 
interestingly, Asp-93 aligns with the postulated actin-binding domain in human CHD1 322 
(Figure 4c). In all three cases the N-termini of the CHDs are the unstructured, intrinsically 323 
disordered regions of the proteins; this was supported by DISOclust and DisEMBL 324 
predictions (data not shown). 325 
 326 
As a further test of this hypothesis, the IQGAP-like protein from the soil amoeba 327 
Dictyostelium discoideum was investigated (gapA; Uniprot O00899) [73, 74]. The significant 328 
feature of this protein is that it does not have any regions that are recognised as CHDs. 329 
Therefore, residues 1-216 were taken and a Phyre2 model produced and subsequently 330 
aligned. The resulting model (Figure 4d) is clearly different from others, but alignment with 331 
human CHD1 showed that the N-terminus of D. discoideum gapA aligned reasonably well 332 
with the postulated binding site in the human protein; coincidently this is also a negatively 333 
charged region with an abundance of polar residues (Figure 4d). So, although D. discoideum 334 
has no recognised CHD, it shows some structural similarity and, therefore, may bind actin 335 
through a novel, functionally equivalent domain. 336 
 337 
Discussion 338 
It has been proposed that there are two actin binding domains used by some CHD-containing 339 
proteins [75-78]. However, in IQGAP1, one CHD is sufficient for actin binding [39].  The 340 
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experimental work presented here demonstrated that the stoichiometry of the interaction is 341 
1:1.  Here we propose that the regions identified in this work (and the polar, intrinsically 342 
disordered analogous regions in other IQGAP-like proteins) form at least part of the initial 343 
interface between the proteins. We believe this could be a lower affinity interface associated 344 
with transient hydrogen bonds and electrostatic interactions that precedes conformational 345 
change and tighter binding at other sites.  We further note that calmodulin has been 346 
previously predicted to interact with the same part of the CHD and speculate that direct 347 
competition for the binding site may be a regulatory mechanism [44].  Further analyses are 348 
necessary to fully characterise the interactions between these proteins. 349 
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Figure legends 557 
Figure 1:  Crosslinking of the CHD of human IQGAP1 (CHD1, 27 μM) and actin (23 μM) by 558 
EDC.  The products of the reaction were resolved by 12.5% SDS-PAGE and visualised by 559 
staining with Coomassie blue.  M, molecular mass markers (masses are shown to the left of 560 
the gel in kDa); A, actin; C, CHD1; AC actin and CHD.  In the control lanes, CHD1 (27 µM) 561 
and actin (23 µM) were incubated with crosslinker under identical conditions.  The additional 562 
bands in the actin lane most likely represent actin dimers and oligomers.  Note that, due to the 563 
equilibrium nature of the interaction and the short half-life of EDC, the crosslinking reaction 564 
does not go to completion.  Therefore, some non-crosslinked product remains visible in lane 565 
AC. 566 
 567 
Figure 2:  Predicted structure of the CHD1/α-actin complex.  α-Actin is shown on the left of 568 
both space-filling (top) and cartoon (bottom left) models in green.  An enlarged image of the 569 
potential interaction site and key residues is also shown (bottom right).  α-Actin residue 570 
labels are in green whilst those belonging to CHD1 are in blue. 571 
 572 
Figure 3:  FIRST/FRODAN flexibility predictions for (a) CHD1 and (b) α-actin.  DISOclust 573 
predicted disordered regions in (c) CHD1 and (d) α-actin 574 
 575 
Figure 4:  Alignments of the predicted structures of the CHD from the IQGAP-like proteins 576 
from (a) C. elegans, (b) H. vulgaris and (c) S. cerevisiae with human CHD1 (green in all 577 
three alignments).  (d) D. discoideum IQGAP-like protein gapA has an atypical CHD-like 578 
structure at the N-terminus.  Structural alignment of this domain with human CHD1 showing 579 
coincident polar, charged residues (human CHD1 in green). 580 
 581 
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Supplementary Figure S1:  Results from the Proface server revealed surface-exposed, 582 
potentially interacting residues. 583 
 584 
Supplementary Figure S2:  Results from DisEMBL reveal potentially flexible residues 585 
(highlighted in yellow). 586 
 587 
Supplementary Figure S3:  Protein sequence alignments of the N-termini of IQGAP-like 588 
proteins from a variety of species. 589 
 590 
 591 
CHD1 
Actin 
CHD-Actin 
116 
66 
45 
35 
25 
18 
14 
M A C AC 

(a) 
(d) (c) 
(b) 
(a) (b) 
(c) (d) 


